October 2009 Grants
Albanesi, J., NIH, Type II P1 4-Kinases in Cell Signaling, $64,089 (supplement); Altschuler, S., NIH, Turnkey Solution for Image Phenotype Classification, $200,000; Auchus, R., NIH, Activation of Androgen Biosynthesis and Drug Metabolism by Cytochrome b5, $220,000; Blount, P., NIH, Molecular Mechanisms of Mechanosensitive Channel Gating, $157,500 (supplement); Booth, T., NIH/CureSearch-NCCF, Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma, $3,750.
Chen, D., Dept. of Energy/Univ. of Calif./Lawrence Berkeley Natl. Lab, Structural Cell Biology of DNA Repair Machines, $63,000; Corey, D., NIH, Recognition of Chromosomal DNA by Chemically Modified Oligonucleotides, $192,000; Corey, D., NIH, Recognition of Chromosomal DNA by Double-Stranded RNA, $108,826 (supplement); Cowan, C., NIH/Mount Sinai School of Med., Molecular Neurobiology of Drug Addiction, $46,350; De Haven, M., NIH, The Goodnews (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial, $377,399.Boothman, D., NIH, Use of Beta-Lapachone for Lung Cancer Chemotherapy, $56,579 (supplement); Brown, E.S., NIH, Quetiapine for Bipolar Disorder and Alcohol Dependence, $12,733 (supplement); Brown, K., NIH/Duke University Medical Center, Development of Novel Therapies for NIDDM: Core B: Gene Targeting Core, $57,313; Burgess, S., NIH/Duke University Medical Center, Development of Novel Therapies for NIDDM, $68,592; Chan, R., NIH/McGill Univ., Design, Construction and Evaluation of Implants for Vocal Fold Alternation and Reconstruction, $58,835.
Diaz-Arrastia, R., Dept. of Edu., North Texas Traumatic Brain Injury Model System, $389,657; Diaz-Arrastia, R., NIH, Phase II Randomized Controlled Trial of Brain Tissue Oxygen Monitoring, $702,164; Diaz-Arrastia, R., NIH, Traumatic Brain Injury Clinical Trials Network, $269,466; Falck, J., NIH/Univ. of Cincinnati, P450 Eicosanoids Reduce Inflammation and Promote Recovery After Brain Injury, $21,875; Fontoura B., NIH, Regulation of mRNA Export by Viral Proteins, $170,000 (supplement).
Frohman, E., NIH, A Prospective Evaluation of Immune System Function in MS Patients Treated With Immune Modulators, $54,824; Gardner, K., NIH, High Throughput Screen Development for Modulators of PAS/Coactivator Interactions, $100,000.
Habib, A., NIH, A Role of RIP1 in Gliomagenesis, $249,206; Hendrixson, D., NIH, Campylobacter Jejuni Flagellar Regulation and Synthesis, $114,971; Halm, E., NIH, Long Term Outcomes of Carotid Endarterectomy in the Elderly, $331,315; Hiesinger P., NIH, Regulation of Synaptic Specificity in the Visual System by Intracellular Traffick, $159,318 (supplement); Hill, J., NIH, Functional Genomics of Complex Vascular Disease, $493,180.
Kliewer, S., NIH/Van Andel Research Inst., Structure Genomics of Orphan Nuclear Receptors, $14,648; Kulkarni, P., NIH, Novel PET Imaging Agents for Early Diagnosis of Plaque Deposition in Alzheimer’s, $240,031; Kurian, B., NIH/Feinstein Inst. of Med. Research, Recovery After the Initial Schizophrenia Episode (RAISE), $323,783; Kuro-o, M., NIH Effects of Klotho Protein on Aging and Metabolism, $328,000 (supplement); Leavey, P., NIH/CureSearch-NCCF, Children’s Oncology Group Chair’s Grant, $11,387.
Lee, W., NIH, A Multicenter Study of Acute Liver Failure in Adults, $818,431 (supplement); Leveno, K., NIH, NICHD Maternal/Fetal Medicine Units Network, $128,910; Leveno, K., NIH, NICHD Maternal/Fetal Medicine Units Network, $110,740; Lister, G., NIH, National Children’s Study, $505,964; Liu, Q., NIH, Biochemical Studies of Drosophila RNA-Induced Silencing Complex, $250,000.
Lu, H., NIH/UT Dallas, Neuroimaging of Dedifferentiation and Memory Across the Lifespan, $10,545; Lu, Q., NIH, Olig2 in Oligodendrocyte Myelination and Remyelination, $32,379 (supplement); Luo, X., NIH, Structure and Function of Spindle Checkpoint Proteins, $175,000; Mahony, L., NIH/New England Research Ins., Pediatric Heart Disease Clinical Research Network, $53,334; Malloy, C., NIH/Med. Coll. of Georgia, Coordinating and Bioinformatics Unit for the AMDCC/MMPC, $336,758.
McKnight, S., NIH, Discovery, Characterization and Preclinical Development of Pro-Neurogenic Drugs, $794,877; McKnight, S., NIH/Mount Sinai School of Med., Neural Substrates for Appetitive Behavior in Mood and Motivation, $70,000; Millner, L., NIH/Houston Acad. of Med., Ventanilla de Salud Online Resource Training Project, $5,000; Monteggia, L., NIH/Mount Sinai School of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $45,000; Niederkorn, J., NIH/Baylor Coll. of Med., Environmentally Induced Ocular Surface Inflammation Mimicking Sjogren’s Syndrome, $30,000.
Nwariaku, F., NIH, Pathophysiological Biochemical Changes of Thermal Injury, $871,125; Okada, P., NIH/Children’s Research Ins., Lorazepam Efficacy and Safety Study, $212,630; Phillips, M., NIH, Polyamine and Trypanothione Metabolism in Trypanosoma Brucei, $250,000; Rao, U., NIH, Treatment Prediction in Adolescent and Adult Depression, $213,341; Raskin, P., NIH, Pioglitazone Preserves Insulin Secretion in Type 1 Diabetes, $404,574.
Roth, M., NIH, A Concerted Attack on Patient-Specific Oncogenic Vulnerabilities in Lung Cancer, $1,409,296; Schaffer, J., NIH, NICHD Pelvic Floor Disorders Network, $148,759 (supplement); Schwartz, J., NIH, “Smart” Radiolabels to Image Macromolecular Interactions, $25,897; Scott, M., NIH, Orexin and Leptin Regulation of Feeding and Addictive Behavior in the VTA, $82,090; Self, D., NIH/Mount Sinai School of Med., Molecular Neurobiology of Drug Addiction, $164,800.
Sharifi, N., Dept. of Defense, Mechanisms of AR Activation With SOD 2 Silencing and Implications for Castration-Resistant Prostate Cancer, $120,412; Shaul, P., NIH, CRP, eNOS and Endothelial Dysfunction, $346,312; Sherry, A.D., NIH/Duke Univ. Med. Ctr., Development of Novel Therapies for NIDDM, $268,332; Skinner, C., NIH/Indiana University, Promoting Breast Cancer Screening Via Computer V Phone, $30,845; Snell, W., NIH, Gamete Membrane Adhesino and Fusion During Fertilization, $84,000 (supplement).
Story, M., NASA/UT Med. Branch, NASA Specialized Centers for Research on Radiation Carcinogenesis, $130,370; Suel, G., Cornell Univ./NSF, CDI Type 1: Distilling Freeform Natural Laws From Experimental Data, $84,586; Sun, X., NIH/Texas A & M Research Foundation, Molecular Recognition in Dendrimers Based on Melamine, $68,400; Tamminga, C., NIH, Treating Cognition in Schizophrenia, $45,000; Tamminga, C., NIH/Mount Sinai School of Med., Neural Substrates for Appetitive Behavior in Mood and Motivation, $90,000.
Terada, L., NIH, Training Program in Lung Biology and Disease, $177,582; Thompson, L., and Fullinwider, J., NIH/Houston Acad. of Med., Action on Health Disparities: Global and Local, $7,975, Vazquez, M., NIH, Anatomic and Functional Predictors of Arteriovenous Fistula Maturation, $217,084; Vazquez, M., NIH, Anatomic and Functional Predictors of Arteriovenous Fistula Maturation, $110,500 (supplement); Wakeland, E., NIH/Baylor Research Inst., Center for Lupus Research, $26,750.
Willson, J., DOD, Nanotechnology in Cellular Therapies, $834,750; Yanagisawa, M., NIH/Mount Sinai School of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $40,000; Yu, H., NIH, Regulation of the Anaphase-Promoting Complex by the Spindle Checkpoint, $85,000 (supplement); Zhang, R., NIH, Mild Cognitive Impairment: Cerebrovascular Dysfunction and Exercise Training, $419,472; Zhang, X., NIH, Regulation Mechanisms for the GTPase Activating Protein Domain of Plexins, $200,000; Zigman, J., NIH, Identification of Central Targets for Ghrelin, $116,072.
Cobb, M., Amer. Diabetes Assn., MAP Kinases in Beta-Cell Function, $36,900; Dowling, M., Doris Duke Charitable Fndtn., PFAST: Patent Foramen Ovale and Stroke in Sickle Cell Disease, $150,000; Frohman, E., Natl. MS Soc., Modeling the Pathophysiology of Uhthoff’s Phenomenon in Multiple Sclerosis, $168,182; Huang, C., Genzyme Corp., Klotho Protection of Glomerular Proteinuria via TRPC6, $43,479.
Pelz, M., American Assn. for Thoracic Surgery, Preservation and Resuscitation of Donor Hearts for Transplantation by Continuous Coronary Sinus Perfusion, $80,000; Takahashi, J., NARSAD Research Grants, Role of CREB in the Synchronization of Circadian Pacemaker Neurons, $41,187 (Izumo, M., fellow); Taurog, J., Arthritis Fndtn., Targeted Gene Deletion in Rats: Application to a Rate Model of Arthritis, $87,963; Ward, E.S., Natl. MS Soc., Antigen Targeting and Tolerance in Murine EAE, 157,037.
Pharmaceutical studies, dollar amounts not available
Carr, B., A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Study Drug in Subjects With Endometriosis; Choy, H., A Randomized, Phase I/II Study of Study Drug in Combination With High-Dose Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer; Frenkel, E., A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Study Drug Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer.
Frohman, E., A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing-Two Annual Cycles of Intravenous Low- and High-Dose Study Drug to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients With Relapsing-Remitting Multiple Sclerosis Who Have Relapsed on Therapy; Fu, Q., Long-Term Effects of Study Drug With or Without Amlodipine on Sympathetic Neural Control and Ventricular-Arterial Function in Elderly Hypertensive Patients; Glazer, C., A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Safety and Efficacy of Treatment With Study Drug or Golimumab in Subjects With Chronic Sarcoidosis.
Hughes, R., A Phase I Study Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Study Drug Administered Every Three Weeks to Patients With Extensive-Stage Small-Cell Lung Cancer; Hutchison, M., A Multicenter, Open-Label, Single-Arm Study Assessing Dyad (Subject and Caregiver) Perception of Convenience and Preference of the Newly Developed Study Device; Maher, E., A Randomized Phase II Study of Maintenance Study Drug vs. Observation in Stable or Responding Stage IIIB/IV Non-Small-Cell Lung Cancer Patients.
Olsen, N., A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Study Drug in Patients With Moderately to Severely Active Systemic Lupus Erythematosus; Pandya, A., A Randomized, Double-Blind, Double-Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Study Drug Ointment, 1 percent, vs. Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus; Swaroop, P., A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Study Drug Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Previously Treated With TNF Antagonist Therapy.
Torres, F., Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Oral Study Drug (1 mg, 1.5 mg, 2 mg, or 2.5 mg TID) in Patients With Symptomatic Pulmonary Arterial Hypertension (PATENT-1 Study); Vernino, S., A Multicenter, Open-Label Study to Assess the Effect of Study Drug on 24-Hour Blood Pressure Profile in the Subjects With Primary Autonomic Failure, Dopamine-Beta-Hydroxylase Deficiency or Nondiabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension.